After successful results of dupilumab [10], a monoclonal antibody directed against α subunit of interleukine (IL)-13 e IL-4 receptor, several clinical trials are actually ongoing to approve new target molecules for the treatment of severe AD: monoclonal antibodies anti IL-13 [11,12] (tralokinumab and lebrikizumab), anti IL-31 [13] (nemolizumab), and small molecules, such as the janus kinasis (JAK) inhibitors [14] (abrocitinib, baricitinib, and upadacitinib). This evidence concerns the gene IL13 and Alzheimer disease.